Neuropathic pain phenotyping as a predictor of treatment response in painful diabetic neuropathy: data from the randomized, double-blind, COMBO-DN study.
Bouhassira D, Wilhelm S, Schacht A, Perrot S, Kosek E, Cruccu G, Freynhagen R, Tesfaye S, Lledó A, Choy E, Marchettini P, Micó JA, Spaeth M, Skljarevski V, Tölle T.
Bouhassira D, et al.
Pain. 2014 Oct;155(10):2171-9. doi: 10.1016/j.pain.2014.08.020. Epub 2014 Aug 27.
Pain. 2014.
PMID: 25168665
Free article.
Clinical Trial.
In patients not responding to initial 60 mg/d duloxetine, adding 300 mg/d pregabalin for combination treatment was particularly effective regarding the dimensions pressing pain and evoked pain, whereas maximizing the duloxetine dose to 120 mg/d appeared more benefic …
In patients not responding to initial 60 mg/d duloxetine, adding 300 mg/d pregabalin for combination treatment was particularly effective re …